These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 14728028)

  • 1. Therapeutic potential for endothelin receptor antagonists in cardiovascular disorders.
    Spieker LE; Noll G; Lüscher TF
    Am J Cardiovasc Drugs; 2001; 1(4):293-303. PubMed ID: 14728028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Endothelin A receptor antagonists in congestive heart failure: blocking the beast while leaving the beauty untouched?
    Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
    Heart Fail Rev; 2001 Dec; 6(4):301-15. PubMed ID: 11447305
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future?
    Spieker LE; Noll G; Ruschitzka FT; Lüscher TF
    J Am Coll Cardiol; 2001 May; 37(6):1493-505. PubMed ID: 11345356
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs.
    Lüscher TF; Barton M
    Circulation; 2000 Nov; 102(19):2434-40. PubMed ID: 11067800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapeutic potential of endothelin receptor antagonists in cardiovascular disease.
    Barton M; Kiowski W
    Curr Hypertens Rep; 2001 Aug; 3(4):322-30. PubMed ID: 11470015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential Role of Endothelin in Early Vascular Aging.
    Trindade M; Oigman W; Fritsch Neves M
    Curr Hypertens Rev; 2017; 13(1):33-40. PubMed ID: 28413991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The clinical potential of endothelin receptor antagonists in cardiovascular medicine.
    Ferro CJ; Webb DJ
    Drugs; 1996 Jan; 51(1):12-27. PubMed ID: 8741230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The endothelin system in pulmonary arterial hypertension.
    Galié N; Manes A; Branzi A
    Cardiovasc Res; 2004 Feb; 61(2):227-37. PubMed ID: 14736539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endothelin in atherosclerosis: importance of risk factors and therapeutic implications.
    d'Uscio LV; Barton M; Shaw S; Lüscher TF
    J Cardiovasc Pharmacol; 2000; 35(4 Suppl 2):S55-59. PubMed ID: 10976783
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Endothelin and endothelin antagonists: pharmacology and clinical implications.
    Lüscher TF; Wenzel RR
    Agents Actions Suppl; 1995; 45():237-53. PubMed ID: 7717186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary hypertension caused by congestive heart failure is ameliorated by long-term application of an endothelin receptor antagonist. Increased expression of endothelin-1 messenger ribonucleic acid and endothelin-1-like immunoreactivity in the lung in congestive heart failure in rats.
    Sakai S; Miyauchi T; Sakurai T; Yamaguchi I; Kobayashi M; Goto K; Sugishita Y
    J Am Coll Cardiol; 1996 Nov; 28(6):1580-8. PubMed ID: 8917275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enrasentan, an antagonist of endothelin receptors.
    Cosenzi A
    Cardiovasc Drug Rev; 2003; 21(1):1-16. PubMed ID: 12595914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Endothelin in the pulmonary circulation with special reference to hypoxic pulmonary vasoconstriction.
    Holm P
    Scand Cardiovasc J Suppl; 1997; 46():1-40. PubMed ID: 9265559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Possible therapeutic role of endothelin antagonists in cardiovascular disease.
    Ram CV
    Am J Ther; 2003; 10(6):396-400. PubMed ID: 14624276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endothelin antagonism in experimental ischemic heart failure: hemodynamic, structural and neurohumoral effects.
    Mulder P; Richard V; Thuillez C
    Heart Fail Rev; 2001 Dec; 6(4):295-300. PubMed ID: 11447304
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endothelin receptor antagonists in cardiology clinical trials.
    Neunteufl T; Berger R; Pacher R
    Expert Opin Investig Drugs; 2002 Mar; 11(3):431-43. PubMed ID: 11866670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.
    Doggrell SA
    Expert Opin Investig Drugs; 2002 Nov; 11(11):1537-52. PubMed ID: 12437501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual ET(A)/ET(B) vs. selective ET(A) endothelin receptor antagonism in patients with pulmonary hypertension.
    Opitz CF; Ewert R
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():1-9. PubMed ID: 16919004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor antagonism in pulmonary arterial hypertension--a role for selective ET(A) inhibition?
    Jacobs A; Preston IR; Gomberg-Maitland M
    Curr Med Res Opin; 2006 Dec; 22(12):2567-74. PubMed ID: 17166339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of endothelin in the control of peripheral vascular tone in human hypertension.
    Taddei S; Virdis A; Ghiadoni L; Sudano I; Magagna A; Salvetti A
    Heart Fail Rev; 2001 Dec; 6(4):277-85. PubMed ID: 11447302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.